Image based prediction of aggressive early lung cancer in lung cancer screening populations

点击翻译按钮获取中文摘要

1) Brief description of the context of the research including potential impactLung cancer screening invites high risk subjects to have a CT scan of their lungs to identify early treatable lung cancer. By 2028 approximately 500-750,000 subjects will have a CT scan of their lungs annually in the National UK lung cancer screening program. 2-3% of screened subjects will have a lung cancer. Lung cancers can show differing rates of growth and spread to lymph nodes, and some lung cancers, despite treatment can recur. Identifying potentially aggressive lung cancers at an early stage could transform lung cancer management worldwide. Cancers expected to be aggressive could be treatment with extra chemotherapy prior to surgery. Our study will analyse data from two UCL studies: SUMMIT and ASCENT. The SUMMIT study is one of the largest lung cancer screening studies in the world which has scanned >13,000 subjects annually to identify lung cancer. The ASCENT study comprises all SUMMIT study patients where a lung cancer was diagnosed. The cancers in the ASCENT study have been genotyped and have longitudinal outcome data collected.This study aims to correlate imaging features of lung cancer growth with clinical and genomic mutational markers of aggression.2) Aims and Objectives Identify image-based features of malignant lung nodules on low-dose CT scans that predict aggressive disease.Evaluate mediastinal lymph node change as a predictor of aggressive disease.Identify genomic signatures on imaging data that can predict aggressive disease.3) Novelty of Research MethodologyDefining aggression in early lung cancer. Aggression currently has no formal medical definition, but creating this could be valuable for many cancer typesUse of time-series deep learning models on medical imaging considering lung and extra-lung features to predict disease progressionNovel histopathological-genomic-imaging correlations to delineate a multidimensional risk score predictive of aggressive early lung cancer4) Alignment to EPSRC's strategies and research areasEPSRC Strategic Priorities: transforming health and healthcareEPSRC Research Portfolio and Priorities: healthcare technologies5) Any companies or collaborators involvedN/A